
    
      After first-line treatment of FOLFOX/FOLFIRI/FOLFOXIRI plus Cetuximab failure and defined as
      RAS/BRAF wild-type by molecular detection of cycle tumor DNA, the patients will be treated
      with Cetuximab and Irinotecan as a second-line or third-line treatment.
    
  